Chengyou Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chengyou Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
A. S. M. Zisanur Rahman
Affiliation Department of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
1 shared publication- Andrew M. Hogan
Department of Microbiology, University of Manitoba
1 shared publication Hunter Sturm
Affiliation Department of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada
1 shared publication- Pingzhao Hu
Department of Computer Science Western University London ON Canada
1 shared publication Rebecca Davis
Affiliation Department of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada
1 shared publication- Silvia T. Cardona
Department of Microbiology, University of Manitoba
1 shared publication
Latest Publications
- Open Access
- 13 October 2022
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 18 (10) , e1010613
A machine learning model trained on a high-throughput antibacterial screen increases the hit rate of drug discovery
Screening for novel antibacterial compounds in small molecule libraries has a low success rate. We applied machine learning (ML)-based virtual screening for antibacterial activity and evaluated its predictive power by experimental validation. We first binarized 29,537 compounds according to their growth inhibitory activity (hit rate 0.87%) against the antibiotic-resistant bacterium Burkholderia cenocepacia and described their molecular features with a directed-message passing neural network (D-MPNN). Then, we used the data to train an ML model that achieved a receiver operating characteristic (ROC) score of 0.823 on the test set. Finally, we predicted antibacterial activity in virtual libraries corresponding to 1,614 compounds from the Food and Drug Administration (FDA)-approved list and 224,205 natural products. Hit rates of 26% and 12%, respectively, were obtained when we tested the top-ranked predicted compounds for growth inhibitory activity against B. cenocepacia, which represents at least a 14-fold increase from the previous hit rate. In addition, more than 51% of the predicted antibacterial natural compounds inhibited ESKAPE pathogens showing that predictions expand beyond the organism-specific dataset to a broad range of bacteria. Overall, the developed ML approach can be used for compound prioritization before screening, increasing the typical hit rate of drug discovery.
- 13 October 2022
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 18 (10) , e1010613
Open AccessA machine learning model trained on a high-throughput antibacterial screen increases the hit rate of drug discovery
Screening for novel antibacterial compounds in small molecule libraries has a low success rate. We applied machine learning (ML)-based virtual screening for antibacterial activity and evaluated its predictive power by experimental validation. We first binarized 29,537 compounds according to their growth inhibitory activity (hit rate 0.87%) against the antibiotic-resistant bacterium Burkholderia cenocepacia and described their molecular features with a directed-message passing neural network (D-MPNN). Then, we used the data to train an ML model that achieved a receiver operating characteristic (ROC) score of 0.823 on the test set. Finally, we predicted antibacterial activity in virtual libraries corresponding to 1,614 compounds from the Food and Drug Administration (FDA)-approved list and 224,205 natural products. Hit rates of 26% and 12%, respectively, were obtained when we tested the top-ranked predicted compounds for growth inhibitory activity against B. cenocepacia, which represents at least a 14-fold increase from the previous hit rate. In addition, more than 51% of the predicted antibacterial natural compounds inhibited ESKAPE pathogens showing that predictions expand beyond the organism-specific dataset to a broad range of bacteria. Overall, the developed ML approach can be used for compound prioritization before screening, increasing the typical hit rate of drug discovery.